Casanillo, Matias V.
HRN: 27-93-19 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/16/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
10/16/2025
10/30/2025
IV
2.25mg
Q6
DM Foot
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes